IVA Nasdaq

Inventiva S.A.

IVA | $3.45 7.14% 1.83% 12K

(0.0% 1d) (-15.3% 1m) (18.4% 1y) (0.0% 2d) (0.0% 3d) (-1.8% 7d) (-40.22% volume)
Earnings Calendar:
Market Cap: $ 181,046,299
http://www.inventivapharma.com
Sec Filling | Patents | 88 employees

(FR) Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centred on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.

drug discovery fibrosis treatment housing nuclear

add to watch list Paper trade email alert is off

Press-releases

Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F
Published: 2024-04-03 (Crawled : 20:00) - globenewswire.com
IVA | $3.45 7.14% 1.83% 12K

Health Technology

| -11.54% | O: 3.02% H: 1.07% C: -2.4%
report universal

Inventiva announces the nomination of Andre Turenne as Director
Published: 2024-03-28 (Crawled : 07:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -7.02% | O: -1.17% H: 0.0% C: -0.89%
SNY | News | $45.39 -1.56% -1.58% 4.3M

Health Technology

| -8.47% | O: -0.96% H: 0.0% C: 0.0%
IVA | $3.45 7.14% 1.83% 12K

Health Technology

| -15.71% | O: -1.83% H: 0.0% C: -3.47%

Inventiva reports its 2023 full-year results
Published: 2024-03-27 (Crawled : 20:00) - globenewswire.com
IVA | $3.45 7.14% 1.83% 12K

Health Technology

| -15.71% | O: -1.83% H: 0.0% C: -3.47%
results

Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results
Published: 2024-03-22 (Crawled : 20:00) - globenewswire.com
IVA | $3.45 7.14% 1.83% 12K

Health Technology

| Email alert Add to watchlist
presentation publication financial results

Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D
Published: 2024-03-18 (Crawled : 20:00) - globenewswire.com
IVA | $3.45 7.14% 1.83% 12K

Health Technology

| -26.15% | O: -9.4% H: 0.0% C: -12.66%
positive results study

Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D
Published: 2024-03-13 (Crawled : 20:00) - globenewswire.com
IVA | $3.45 7.14% 1.83% 12K

Health Technology

| -18.48% | O: 1.27% H: 1.5% C: 0.25%
trial results

Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed
Published: 2024-03-07 (Crawled : 21:00) - globenewswire.com
IVA | $3.45 7.14% 1.83% 12K

Health Technology

| -11.05% | O: 4.42% H: 5.78% C: 2.25%
trial nash

Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3
Published: 2024-02-15 (Crawled : 22:00) - globenewswire.com
IVA | $3.45 7.14% 1.83% 12K

Health Technology

| -18.27% | O: -15.23% H: 6.88% C: -0.9%
year update trial financial

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Published: 2024-01-24 (Crawled : 21:00) - globenewswire.com
IVA | $3.45 7.14% 1.83% 12K

Health Technology